Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626078 | 0.93 | DPP4 (0.42) | CHRNB2CHRNA4DPP4DPP8DPP9 | |
| SCHEMBL6625195 | 0.87 | DPP4 (0.44) | CHRNB2CHRNA4DPP4DPP8DPP9 | |
| SCHEMBL3579509 | 0.82 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3576896 | 0.82 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL3573719 | 0.82 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT | |
| SCHEMBL5832150 | 0.75 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6626577 | 0.75 | L3MBTL3 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5832776 | 0.75 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5366888 | 0.74 | CHRNB2 (0.69) | CHRNB2CHRNA4DPP4DPP8DPP9 | |
| SCHEMBL3567497 | 0.74 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | disclosed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1987031-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NeuroSearch A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007090888-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | CHRNA3, CHRNA10, CHRNB3 | CHRNB2 12/4885CHRNA4 8/4885DPP4 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.